{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'To determine the appropriate dose regimen, the population PK simulation was conducted using', 'the pediatric Pop PK model and the pediatric demographic data of Centers for Disease Control', 'and Prevention-National Health and Nutrition Examination Survey (CDC-NHANES) database.', 'The NHANES population of 6 to 11 years is adequate to reflect the inter-subject variability to', 'inform the dosage recommendation in the age group.', 'To account for body size difference in the pediatric population and taking into account the', 'observed large therapeutic indices of dupilumab, a tiered fixed dosing regimen was chosen over', 'weight based (mg/kg) dosing, as this approach offers a potential safety advantage of reducing the', 'risk of dosing errors, as well as dosing convenience for patients by allowing self-administration', 'using a prefilled syringe/device. The dosing regimen was selected as shown below:', 'Dupilumab 200 or 100 mg SC once q2w for children with bw >30 kg or <30 kg, respectively.', 'The predicted exposure at 200 mg q2w in children aged 6 to <12 years weighing more than 30 kg', 'largely overlaps with the observed efficacious exposure in adults at 300 mg and 200 mg q2w and', 'is expected to be well within the adult safe exposure of up to 300 mg qw. Similarly, the lower', 'dose of 100 mg q2w in children less than 30 kg is predicted to provide comparable exposure to', 'that in the heavier children and the adults. Moreover, the estimated range of steady-state Cmax was', 'generally within the range of pediatric exposure in 6 to <12 years observed in AD-1412 which', 'was well tolerated and safe.', 'In summary, the proposed tiered dosing regimen (200 mg q2w weighing >30 kg and 100 mg q2w', 'weighing 30 kg) for children aged 6 to <12 years is expected to provide significant clinical', 'benefit and a safety profile similar to that of older patients.', 'Property of the Sanofi Group - strictly confidential', 'Page 40', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '5', 'STUDY OBJECTIVES', '5.1', 'PRIMARY', 'To evaluate the efficacy of dupilumab in children 6 to <12 years of age with uncontrolled', 'persistent asthma', '5.2', 'SECONDARY', 'To assess the safety and tolerability of dupilumab', 'To evaluate the effect of dupilumab in improving patient reported outcomes (PROs)', 'including health related quality of life (HRQoL)', 'To assess the dupilumab systemic exposure and incidence of anti-drug antibodies (ADA)', 'To evaluate the association between dupilumab treatment and pediatric immune responses', 'to vaccines: any vaccination for tetanus, diphtheria, pertussis and/or seasonal', 'trivalent/quadrivalent influenza vaccine.', '5.3', 'OTHER', 'Exploratory Objectives:', 'To explore baseline and on-treatment levels of biomarkers for their potential to predict and', 'to associate with a treatment response', 'To evaluate the proportion of patients requiring increased dose of ICS or step up in the', 'second controller medication regimen', 'To evaluate the effect of dupilumab on additional PROs', 'Property of the Sanofi Group - strictly confidential', 'Page 41', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '6', 'STUDY DESIGN', '6.1', 'DESCRIPTION OF THE STUDY', 'This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group', 'study assessing the effect of dupilumab administered SC for a maximum of 52 weeks in children 6', 'to <12 years of age with uncontrolled asthma.', '6.2', 'DURATION OF STUDY PARTICIPATION', '6.2.1 Duration of study participation for each patient', 'The study will last up to 68=1 weeks as follows:', \"Screening Period (4=1 weeks) to determine a patient's eligibility status and establish level\", 'of asthma control before randomization.', 'Randomized Treatment Period (up to 52 weeks): treatment with dupilumab or placebo', 'SC injection.', \"Post-treatment Period (12 weeks): to monitor a patient's status when off study drug\", 'treatment for patients not participating in the 1-year long-term extension study.', '6.2.2 Determination of end of clinical trial (all patients)', 'The last patient last visit will occur when either:', 'The last patient has completed the 12-week post-treatment period or', 'The last patient has completed the end-of-treatment (EOT) visit and enrolled in the 1-year', 'long-term extension study.', '6.3', 'INTERIM ANALYSIS', 'No interim analysis is planned for this study.', '6.4', 'STUDY COMMITTEES', '6.4.1 Data Monitoring Committee', \"A data monitoring committee (DMC) is independent from Sponsor's and is commissioned for the\", 'dupilumab clinical development program. This committee is comprised of externally-based', 'individuals with expertise in the diseases under study, biostatistics, or clinical research. The DMC', 'will review and evaluate the safety data during the course of the trial and make appropriate', 'recommendations regarding the conduct of the clinical trial to the Sponsor.', 'Property of the Sanofi Group - strictly confidential', 'Page 42', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}